237 related articles for article (PubMed ID: 28942012)
1. Activation of SRY accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma.
Liu C; Ren YF; Dong J; Ke MY; Ma F; Monga SPS; Wu R; Lv Y; Zhang XF
Cancer Lett; 2017 Dec; 410():20-31. PubMed ID: 28942012
[TBL] [Abstract][Full Text] [Related]
2. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
3. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
4. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.
Zhang XF; Tan X; Zeng G; Misse A; Singh S; Kim Y; Klaunig JE; Monga SP
Hepatology; 2010 Sep; 52(3):954-65. PubMed ID: 20583210
[TBL] [Abstract][Full Text] [Related]
5. Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma.
Xue TC; Zhang L; Ren ZG; Chen RX; Cui JF; Ge NL; Ye SL
Dig Dis Sci; 2015 Feb; 60(2):427-35. PubMed ID: 25274159
[TBL] [Abstract][Full Text] [Related]
6. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
7. Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
Wu XN; Wang MZ; Zhang N; Zhang W; Dong J; Ke MY; Xiang JX; Ma F; Xue F; Hou JJ; Ma ZJ; Wang FM; Liu XM; Wu R; Pawlik TM; Ye K; Yu J; Zhang XF; Lyu Y
J Hepatol; 2024 Jun; 80(6):928-940. PubMed ID: 38336346
[TBL] [Abstract][Full Text] [Related]
8. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis.
Lu M; Hartmann D; Braren R; Gupta A; Wang B; Wang Y; Mogler C; Cheng Z; Wirth T; Friess H; Kleeff J; Hüser N; Sunami Y
BMC Cancer; 2019 Sep; 19(1):887. PubMed ID: 31488102
[TBL] [Abstract][Full Text] [Related]
10. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.
Huang X; Yu C; Jin C; Yang C; Xie R; Cao D; Wang F; McKeehan WL
Mol Carcinog; 2006 Dec; 45(12):934-42. PubMed ID: 16929488
[TBL] [Abstract][Full Text] [Related]
11. SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.
Tsao CM; Yan MD; Shih YL; Yu PN; Kuo CC; Lin WC; Li HJ; Lin YW
Hepatology; 2012 Dec; 56(6):2277-87. PubMed ID: 22767186
[TBL] [Abstract][Full Text] [Related]
12. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.
Zhang N; Chu ES; Zhang J; Li X; Liang Q; Chen J; Chen M; Teoh N; Farrell G; Sung JJ; Yu J
Oncotarget; 2014 Sep; 5(18):8330-40. PubMed ID: 25327562
[TBL] [Abstract][Full Text] [Related]
14. Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation.
Shang N; Bank T; Ding X; Breslin P; Li J; Shi B; Qiu W
Cell Death Dis; 2018 May; 9(5):558. PubMed ID: 29752472
[TBL] [Abstract][Full Text] [Related]
15. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500
[TBL] [Abstract][Full Text] [Related]
16. BOK promotes chemical-induced hepatocarcinogenesis in mice.
Rabachini T; Fernandez-Marrero Y; Montani M; Loforese G; Sladky V; He Z; Bachmann D; Wicki S; Villunger A; Stroka D; Kaufmann T
Cell Death Differ; 2018 Mar; 25(4):708-720. PubMed ID: 29229991
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.
Llorente Izquierdo C; Mayoral R; Flores JM; García-Palencia P; Cucarella C; Boscá L; Casado M; Martín-Sanz P
Am J Pathol; 2011 Mar; 178(3):1361-73. PubMed ID: 21356386
[TBL] [Abstract][Full Text] [Related]
18. Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats.
Dragan YP; Sargent LM; Babcock K; Kinunen N; Pitot HC
Mol Carcinog; 2004 Jul; 40(3):150-9. PubMed ID: 15224347
[TBL] [Abstract][Full Text] [Related]
19. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.
Cheng J; Zhong Y; Chen S; Sun Y; Huang L; Kang Y; Chen B; Chen G; Wang F; Tian Y; Liu W; Feng GS; Lu Z
FASEB J; 2017 Dec; 31(12):5530-5542. PubMed ID: 28842424
[TBL] [Abstract][Full Text] [Related]
20. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo.
Stein TJ; Bowden M; Sandgren EP
Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
